A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

About the trial

Sponsor

AbbVie

Tested

Venetoclax (drug), Acalabrutinib (drug), Obinutuzumab (drug)

Dates

Started 2024-08-05; completion 2028-03

Results posted

Not yet

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 170 adult participants with CLL…

From ClinicalTrials.gov, last updated 2026-04-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $4.2M in research payments for this study in 2025 (283 payments).

Products named: Venclexta

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.